Celiprolol: A Unique Selective Adrenoceptor Modulator
Celiprolol is a β-blocker with a unique pharmacologic profileit is a β1-andrenoceptor antagonist with partial β2 agonist activity. Given this combination of effects, celiprolol may be better described as a elective adrenoreceptor modulator. It has antihypertensive and antianginal properties and is indicated for those uses in various countries around the world. In the United States, however, the proposed indication for this drug will be for the treatment of vascular type Ehlers–Danlos syndrome, a rare connective tissue isorder haracterized by fragile arterial structure and an increased risk of life-threatening vascular complications. By reducing heart rate and pulsatile pressure, celiprolol may reduce the mechanical stress on collagen fibers within the arterial wall and be of benefit in patients with vascular type Ehlers–Danlos syndrome. The largest investigation of celiprolol in vascular Ehlers–Danlos syndrome was prematurely terminated due to ignificant benefit with celiprolol in reducing arterial events in patients with this condition. Celiprolol, therefore, represents a β-blocker that is unique from others in its class in both its pharmacology and clinical applications.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2017 |
|---|---|
| Enthalten in: |
Cardiology in review - (2017) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nawarskas, James J [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.1097/CRD.0000000000000159 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1996347799 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1996347799 | ||
| 003 | DE-627 | ||
| 005 | 20230511181103.0 | ||
| 007 | tu | ||
| 008 | 170901s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CRD.0000000000000159 |2 doi | |
| 028 | 5 | 2 | |a PQ20170901 |
| 035 | |a (DE-627)OLC1996347799 | ||
| 035 | |a (DE-599)GBVOLC1996347799 | ||
| 035 | |a (PRQ)wolterskluwer_health_10_1097_CRD_00000000000001590 | ||
| 035 | |a (KEY)0230615820170000000000000000celiprololauniqueselectiveadrenoceptormodulator | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ZDB |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Nawarskas, James J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Celiprolol: A Unique Selective Adrenoceptor Modulator |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Celiprolol is a β-blocker with a unique pharmacologic profileit is a β1-andrenoceptor antagonist with partial β2 agonist activity. Given this combination of effects, celiprolol may be better described as a elective adrenoreceptor modulator. It has antihypertensive and antianginal properties and is indicated for those uses in various countries around the world. In the United States, however, the proposed indication for this drug will be for the treatment of vascular type Ehlers–Danlos syndrome, a rare connective tissue isorder haracterized by fragile arterial structure and an increased risk of life-threatening vascular complications. By reducing heart rate and pulsatile pressure, celiprolol may reduce the mechanical stress on collagen fibers within the arterial wall and be of benefit in patients with vascular type Ehlers–Danlos syndrome. The largest investigation of celiprolol in vascular Ehlers–Danlos syndrome was prematurely terminated due to ignificant benefit with celiprolol in reducing arterial events in patients with this condition. Celiprolol, therefore, represents a β-blocker that is unique from others in its class in both its pharmacology and clinical applications.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. | ||
| 540 | |a Nutzungsrecht: Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 700 | 1 | |a Cheng-Lai, Angela |4 oth | |
| 700 | 1 | |a Frishman, William H |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiology in review |d Baltimore, Md. : Williams & Wilkins, 1993 |g (2017) |w (DE-627)192211676 |w (DE-600)1294965-6 |w (DE-576)051294540 |x 1061-5377 |7 nnns |
| 773 | 1 | 8 | |g year:2017 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1097/CRD.0000000000000159 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |j 2017 | ||